Multiple reaction monitoring (MRM) and selected reaction monitoring (SRM) quantify predefined proteotypic peptides on a triple quadrupole liquid chromatography-tandem mass spectrometry (LC-MS/MS) schedule (Lange et al. 2008). Teams working on proteolysis-targeting chimera (PROTAC) or other degrader programs often ask whether MRM can report target-protein change after treatment. In project language, MRM reports relative peptide change on a closed panel across frozen dose, time, or molecule arms. It does not by itself prove degradation mechanism, occupancy, or clinical efficacy. The guide below integrates MRM and SRM as a targeted quantitative record with workflow, parameters, limits, and project fit, using degrader contrasts as one common application. It is not a PROTAC chemistry review, not a Western blot replacement slogan, and not a drug-development promise page.

Relative fold change on matched pretreatment remains the usual MRM claim. Amount on named peptides needs stable isotope-labeled internal standard (SIS) peptides and a calibration model in the study matrix (Gerber et al. 2003). Phospho-site or pathway-neighbor peptides are separate assay scopes unless those transitions are closed and validated in the same brief (Bantscheff et al. 2012).

In MtoZ Biolabs targeted offerings, MRM is scoped when the peptide panel is closed, contrast arms are frozen, and matrix-matched transition pilots support the cohort. Service intake appears in SRM-MRM Quantitative Proteomics Services.

What MRM and SRM Cover in Targeted Quantitative Projects

Four scopes belong in the brief and stay separated.

Assay scope is targeted. Only peptides on the inclusion list are scheduled. Open discovery search is outside this record.

Detection scope is one precursor-product transition per dwell period on a triple quadrupole. Quantification uses integrated transition chromatograms after matrix-matched optimization.

Contrast scope names treated versus control, dose, time, or candidate-molecule arms. For degrader studies, harvest time and dose must be declared before peak review.

Claim scope is relative peptide change, or calibrated amount when SIS and a curve are declared. Target knockdown language still sits on peptide surrogates unless protein-level standard design is documented.

MRM and SRM quantify scheduled peptides on a closed panel. They do not certify that a PROTAC removed a protein from a pathway.

MRM Versus PRM, Discovery LFQ, and Antibody Readouts

Route choice follows list status, matrix interference, and the decision the table must support.

Parallel reaction monitoring (PRM) isolates scheduled precursors and records high-resolution product-ion spectra (Peterson et al. 2012). PRM fits when MRM transitions drift after matrix-matched optimization. Route choice after matrix pilot appears in Parallel Reaction Monitoring vs MRM: Which Fits?.

Label-free quantification (LFQ) on unlabeled discovery injections profiles an open or semi-open proteome. Degrader programs still in candidate-finding mode belong in discovery first. Study-stage route matching appears in Targeted Proteomics or Discovery Profiling? Matching MRM, PRM, and Label-Free Routes to Your Study Stage.

Western blot or enzyme-linked immunosorbent assay (ELISA) reports an epitope when an antibody and linear range already exist. MRM does not require an antibody. It still requires a unique, LC-MS-compatible peptide and matched digest.

SIS-supported MRM can report peptide amount. Antibody band intensity is not interchangeable with that unit without a bridging study.

End-to-End Workflow for MRM on Closed Degrader or Treatment Contrasts

A practical MRM spine usually runs as follows.

1. Freeze contrast, dose or time map, and relative versus amount claim.
2. Close the peptide panel for the target and any declared pathway neighbors.
3. Match harvest, extraction, digest, and load across all arms.
4. Optimize transitions on matrix-matched digests, not only on neat standards.
5. Build dwell schedule and retention windows with realistic cycle time.
6. Size biological replicates plus quality control (QC), blanks, and SIS if used.
7. Acquire interleaved study and QC injections when cohort size allows.
8. Integrate peaks; flag failed transitions against prespecified rules.
9. Test predefined contrast only; archive panel version and methods with deliverables.

Steps 1 through 3 protect the sample record. Steps 4 through 9 produce the targeted quantitative record.

Figure 1. MRM comparability depends on matched pretreatment and a locked transition method before dose or time contrasts are tested.

Parameters That Must Be Locked for MRM and SRM

Layer	Parameter that must be declared	Failure mode if ignored
Contrast	Dose, time, and vehicle arms frozen	Post hoc efficacy stories
Panel	Peptide list and protein mapping	Moving targets mid study
Prep	Harvest and digest parity	Peptide-pool shift as knockdown
Transitions	Precursor, products, dwell, collision energy	Neat-standard methods fail in matrix
Schedule	Cycle time versus panel size	Missing peaks at elution
SIS	Spike step aligned to claim	Peptide amount as extract amount
QC	Pools, blanks, and bracket pattern	Undetected batch drift
Phospho or PTM	Separate enrichment if claimed	Unenriched sites as pathway proof
Statistics	Contrast tested only as frozen	Dose relabeling after peaks
Deliverable	Table, transition list, QC notes	Report rebuilt after acquisition

Limits follow the same table. MRM abundance drop after treatment is compatible with degradation, synthesis change, or prep loss. Mechanism claims need orthogonal design. Femtomole-style headlines are not a substitute for matrix-matched pilots. Concurrent pathway proteins need their own closed transitions and QC.

How to Choose MRM for Degrader and Other Targeted Contrasts

Use panel status, matrix pilot, claim unit, and mechanism evidence standard together.

Project need	Route that often fits	Recheck before committing
Closed target peptides, dose or time map	MRM after matrix-matched lock	Open discovery as efficacy table
MRM transitions unstable in matrix	PRM subset or hybrid panel	Whole-panel PRM without need
Target list still open	Label-free LFQ or DIA first	MRM on unnamed proteins
Amount on named peptides	MRM or PRM with SIS and curve	Relative peaks as potency units
Antibody already answers the same epitope	Keep immunoassay in parallel	MRM as automatic replacement
Pathway or phospho neighbors	Separate enriched targeted block	Unplanned extras from one file
Occupancy or ternary-complex claims	Not from MRM abundance alone	Peptide fold change as mechanism

Figure 2. Choose MRM when a closed peptide panel and matched treatment prep fit the contrast; use PRM, discovery, or orthogonal assays when list status or claim unit changes.

Teams with closed target peptides, treatment map, and matrix notes can review MtoZ Biolabs SRM-MRM Quantitative Proteomics Services when those fields are declared in the project record.

Frequently Asked Questions

1. Can MRM evaluate PROTAC efficacy by itself?

MRM can report relative change of closed target peptides across declared treatment arms. Efficacy, degradation mechanism, and structure-activity decisions need study design beyond the MRM table.

2. Is MRM more suitable than Western blot for every degrader study?

No. Antibody assays remain useful when an epitope and linear range already exist. MRM fits multiplex peptide panels and antibody-independent sequences after matrix-matched method lock.

3. Can one MRM method monitor the target and all downstream signaling proteins?

Only peptides on the closed list are quantified. Pathway neighbors need declared transitions, and phospho sites often need enrichment.

4. Does a lower MRM signal prove proteasomal degradation?

No. Signal drop is compatible with several biological and technical causes. Mechanism language needs orthogonal evidence.

5. When should a degrader program stay in discovery instead of MRM?

When off-target or unexpected protein changes are still the question, LFQ or DIA remains the matching block until a shortlist is frozen.

MtoZ Biolabs can discuss MRM and SRM scoping when peptide panel, treatment contrast, and pretreatment parity are documented.

If further evaluation of MRM versus PRM, SIS calibration, or discovery-to-targeted handoff is needed, project details can be submitted for a feasibility review.

Reference

1. V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
2. A.C. Peterson, J.D. Russell, A.A. Klammer, P.F. Doubleday, H. Liu, J.N. Anderson, M.J. MacCoss (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020271
3. S.A. Gerber, J. Rush, O. Stemman, M.W. Kirschner, S.P. Gygi (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A., 100, 6940-6945. https://doi.org/10.1073/pnas.0832254100
4. M. Bantscheff, S. Lemeer, H.U. Haab, B. Kuster (2012). Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem., 404, 939-965. https://doi.org/10.1007/s00216-012-5892-4
5. J. Cox, M.Y. Hein, C.A. Luber, I. Paron, M. Mann (2014). Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics, 13, 2513-2526. https://doi.org/10.1074/mcp.M113.031031